Liver Unit, Carmel Medical Center, Haifa 34363, Israel.
Clin Rheumatol. 2011 Jul;30(7):987-91. doi: 10.1007/s10067-011-1718-1. Epub 2011 Mar 2.
The purpose of this study is to characterize the chronic liver disease (CLD) that may be associated with familial Mediterranean fever (FMF). Twenty-seven patients (mean age, 48 ± 18 years; F/M, 16:11) with FMF who were referred for assessment of CLD were studied. Data regarding FMF and CLD were obtained from patient medical files. Liver biopsy was performed in 21 of 27 patients and deferred in six (cirrhotic coagulopathy in five and one who improved after colchicine dose reduction). Patients with FMF and non-alcoholic fatty liver disease (NAFLD) were compared to matched controls from a cohort of 150 patients with NAFLD per liver biopsy but without FMF. The mean Tel Hashomer severity score was 1.7 ± 0.9. The mean daily dose of colchicine was 1.4 ± 0.4 mg over a mean duration of 21 years ± 10. Seven of ten patients who underwent mutation analysis for FMF were homozygous for M694V. In 15 patients, there was evidence of NAFLD: five with "simple" steatosis, three with non-alcoholic steatohepatitis (NASH), and seven with NASH-cirrhosis. An additional five patients had "cryptogenic" cirrhosis, which in most patients represents the end result of unrecognized NASH, and one had normal liver tissue. Comparing FMF patients with NAFLD to matched controls with NAFLD did not reveal excess of metabolic syndrome in FMF patients. Of our FMF patients, 74% had evidence of NAFLD, 75% of which with severe manifestation. The extremely high proportion of NAFLD in our cohort of FMF patients without overt metabolic syndrome may indicate an unappreciated novel association between FMF and NAFLD.
本研究旨在描述可能与家族性地中海热(FMF)相关的慢性肝病(CLD)。研究了 27 名(平均年龄 48 ± 18 岁;男/女 16:11)因评估 CLD 而转诊的 FMF 患者。从患者病历中获得了有关 FMF 和 CLD 的数据。27 名患者中有 21 名进行了肝活检,6 名患者(5 名因肝硬化凝血功能障碍和 1 名因秋水仙碱剂量减少而改善)推迟了肝活检。将 FMF 伴非酒精性脂肪性肝病(NAFLD)患者与从 150 名接受 NAFLD 肝活检但无 FMF 的患者中匹配的对照组进行比较。Tel Hashomer 严重程度评分平均为 1.7 ± 0.9。秋水仙碱的平均日剂量为 1.4 ± 0.4mg,平均持续时间为 21 年 ± 10 年。对 10 名 FMF 患者进行突变分析的 7 名患者为 M694V 纯合子。在 15 名患者中,有 NAFLD 的证据:5 名单纯性脂肪变性,3 名非酒精性脂肪性肝炎(NASH),7 名 NASH 肝硬化。另外 5 名患者有“隐匿性”肝硬化,在大多数患者中,这代表了未被识别的 NASH 的终末结果,1 名患者的肝组织正常。将 FMF 患者与 NAFLD 匹配的对照组进行比较,并未发现 FMF 患者代谢综合征过多。在我们的 FMF 患者中,74%有 NAFLD 的证据,其中 75%为严重表现。在我们的 FMF 患者队列中,无明显代谢综合征的 NAFLD 比例极高,这可能表明 FMF 和 NAFLD 之间存在一种未被认识到的新关联。